>
GURUFOCUS.COM > STOCK LIST > Healthcare > Drug Manufacturers > Bristol-Myers Squibb Co (NYSE:BMY) > Definitions > GF Value
Switch to:

Bristol-Myers Squibb Co GF Value

: $74.10 (As of Today)
View and export this data going back to 1952. Start your Free Trial

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

  1. Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
  2. GuruFocus adjustment factor based on the company’s past returns and growth.
  3. Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2022-07-04), Bristol-Myers Squibb Co's share price is $76.84. Bristol-Myers Squibb Co's GF Value is $74.10. Therefore, Bristol-Myers Squibb Co's Price-to-GF-Value for today is 1.04.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Bristol-Myers Squibb Co is Fairly Valued.


Bristol-Myers Squibb Co  (NYSE:BMY) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Bristol-Myers Squibb Co's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=76.84/74.10
=1.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bristol-Myers Squibb Co GF Value Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Bristol-Myers Squibb Co Business Description

Bristol-Myers Squibb Co logo
Industry
Healthcare » Drug Manufacturers NAICS : 325412 SIC : 2834
Address
430 East 29th Street, 14th Floor, New York, NY, USA, 10016
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Executives
Vousden Karen H director 345 PARK AVENUE NEW YORK NY 10154
Samuels Theodore R. Ii director 1990 E. GRAND AVE. EL SEGUNDO CA 90245
Haller Julia A director C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Paliwal Dinesh C director 5454 W 110TH STREET OVERLAND PARK KS 66211
Rice Derica W director LILLY CORPORATE CENTER INDIANAPOLIS IN 46285
Emmens Matthew director C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST., ATTN: GENERAL COUNSEL CAMBRIDGE MA 02139
Bertolini Robert J director C/O SCHERING PLOUGH CORP 2000 GALLOPING HILL RD KENILWORTH NJ 070333
Price Paula A director ONE CVS DRIVE WOONSOCKET RI 02895
Yale Phyllis R director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: YALE PHYLLIS R a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Bonney Michael W director 65 HAYDEN AVE LEXINGTON MA 02421
Arduini Peter J director 311 ENTERPRISE DRIVE PLAINSBORO NJ 08536
Santiago Karen Murphy officer: SVP & Controller BRISTOL-MYERS SQUIBB COMPANY RT. 206 & PROVINCE LINE ROAD PRINCETON NJ 08540
Caforio Giovanni director, officer: Chairman and CEO BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVINCELINE ROAD LAWRENCEVILLE NJ 08543
Eid Joseph officer: SVP,Head Glob. Medical Affairs BRISTOL-MYERS SQUIBB COMPANY 3401 PRINCETON PIKE LAWRENCEVILLE NJ 08648
Leung Sandra officer: EVP, General Counsel C/O BRISTOL MYERS SQUIBB CO 345 PARK AVE NEW YORK NY 10164

Bristol-Myers Squibb Co Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)